Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

556 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.
San-Miguel JF, Echeveste Gutierrez MA, Špicka I, Mateos MV, Song K, Craig MD, Bladé J, Hájek R, Chen C, Di Bacco A, Estevam J, Gupta N, Byrne C, Lu V, van de Velde H, Lonial S. San-Miguel JF, et al. Among authors: blade j. Haematologica. 2018 Sep;103(9):1518-1526. doi: 10.3324/haematol.2017.185991. Epub 2018 Jun 28. Haematologica. 2018. PMID: 29954932 Free PMC article. Clinical Trial.
Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome.
San Miguel JF, Almeida J, Mateo G, Bladé J, López-Berges C, Caballero D, Hernández J, Moro MJ, Fernández-Calvo J, Díaz-Mediavilla J, Palomera L, Orfao A. San Miguel JF, et al. Among authors: blade j. Blood. 2002 Mar 1;99(5):1853-6. doi: 10.1182/blood.v99.5.1853. Blood. 2002. PMID: 11861305 Free article.
Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
Alegre A, Granda A, Martínez-Chamorro C, Díaz-Mediavilla J, Martínez R, García-Laraña J, Lahuerta JJ, Sureda A, Bladé J, de la Rubia J, Fernández-Rañada JM, San Miguel J; Spanish Registry of Transplants in Multiple Myelomas; Spanish Group of Hemopoietic Transplant (GETH); PETHEMA. Alegre A, et al. Among authors: blade j. Haematologica. 2002 Jun;87(6):609-14. Haematologica. 2002. PMID: 12031917
Bortezomib is an efficient agent in plasma cell leukemias.
Esparís-Ogando A, Alegre A, Aguado B, Mateo G, Gutiérrez N, Bladé J, Schenkein D, Pandiella A, San Miguel JF. Esparís-Ogando A, et al. Among authors: blade j. Int J Cancer. 2005 Apr 20;114(4):665-7. doi: 10.1002/ijc.20793. Int J Cancer. 2005. PMID: 15609327
Genetic abnormalities and patterns of antigenic expression in multiple myeloma.
Mateo G, Castellanos M, Rasillo A, Gutiérrez NC, Montalbán MA, Martín ML, Hernández JM, López-Berges MC, Montejano L, Bladé J, Mateos MV, Sureda A, de la Rubia J, Díaz-Mediavilla J, Pandiella A, Lahuerta JJ, Orfao A, San Miguel JF. Mateo G, et al. Among authors: blade j. Clin Cancer Res. 2005 May 15;11(10):3661-7. doi: 10.1158/1078-0432.CCR-04-1489. Clin Cancer Res. 2005. PMID: 15897562
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Richardson PG, et al. Among authors: blade j. N Engl J Med. 2005 Jun 16;352(24):2487-98. doi: 10.1056/NEJMoa043445. N Engl J Med. 2005. PMID: 15958804 Free article. Clinical Trial.
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Bladé J, Rosiñol L, Sureda A, Ribera JM, Díaz-Mediavilla J, García-Laraña J, Mateos MV, Palomera L, Fernández-Calvo J, Martí JM, Giraldo P, Carbonell F, Callís M, Trujillo J, Gardella S, Moro MJ, Barez A, Soler A, Font L, Fontanillas M, San Miguel J; Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA). Bladé J, et al. Blood. 2005 Dec 1;106(12):3755-9. doi: 10.1182/blood-2005-03-1301. Epub 2005 Aug 16. Blood. 2005. PMID: 16105975 Free article. Clinical Trial.
The future role of thalidomide in multiple myeloma.
Boccadoro M, Blade J, Attal M, Palumbo A. Boccadoro M, et al. Among authors: blade j. Acta Haematol. 2005;114 Suppl 1:18-22. doi: 10.1159/000087040. Acta Haematol. 2005. PMID: 16166768 Review.
556 results